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Norovirus (NoV) is a main cause of acute gastroenteritis across all ages worldwide. NoV vaccine candidates currently in clinical
trials are based on noninfectious highly immunogenic virus-like particles (VLPs) delivered intramuscularly (IM). Since NoV is
an enteric pathogen, it is likely that mucosal immunity has a signiﬁcant role in protection from infection in the intestine. Due to
the fact that IM delivery of NoV VLPs does not generate mucosal immunity, we investigated whether NoV genotype GII.4 VLPs
coadministered with aluminum hydroxide (Al(OH)3) or monophosphoryl lipid A (MPLA) would induce mucosal antibodies in
mice. Systemic as well as mucosal IgG and IgA antibodies in serum and intestinal and nasal secretions were measured. As
expected, strong serum IgG, IgG1, and IgG2a antibodies as well as a dose sparing eﬀect were induced by both Al(OH)3 and
MPLA, but no mucosal IgA antibodies were detected. In contrast, IN immunization with GII.4 VLPs without an adjuvant
induced systemic as well as mucosal IgA antibody response. These results indicate that mucosal delivery of NoV VLPs is needed
for induction of mucosal responses.
1. Introduction
The need for norovirus (NoV) vaccine is apparent, as NoV is
the most common cause of acute viral gastroenteritis world-
wide with approximately 200,000 annual deaths [1]. It infects
humans of all ages, but children <5 years of age, the elderly,
and immunocompromised individuals are at the highest risk.
The most advanced NoV vaccine in phase II clinical trials is
based on virus-like particles (VLPs) administered intramus-
cularly (IM) with aluminum hydroxide (Al(OH)3) [2] or a
combination of Al(OH)3 and monophosphoryl lipid A
(MPLA) [3–6]. Alternative intranasal (IN) administration
of NoV VLPs has previously been evaluated as well [7, 8].
Despite the lack of the deﬁnite vaccine-associated correlate
of protection for NoV, mucosal immunity is known to play
a signiﬁcant role in protection from infection and disease
caused by enteric pathogens, including NoV [9–12].
At present, there are only a few adjuvants approved for
human use, and none for mucosal delivery [13, 14]. Alumi-
num salts (Alum) and MPLA are adjuvants commonly
included in the formulation of licensed protein subunit vac-
cines, such as VLP-based vaccines against human papilloma
virus (Cervarix®, Gardasil®) and hepatitis B virus (Engerix-
B®, Recombivax HB®). Alum, the ﬁrst and predominant
adjuvant in human vaccines, is employed to stabilize the vac-
cine antigen and also as a delivery system [13, 15]. MPLA, a
new-generation toll-like receptor- (TLR-) based adjuvant, is
a TLR4 agonist, which activates innate immunity [16, 17],
thereby inﬂuencing the development of adaptive immunity.
Recently, alum has been described to possess immunomodu-
latory features as well [18]. Both of these adjuvants stimulate
systemic immune responses, when administered parenterally
with the vaccine antigens. However, their eﬀect on antigen-
speciﬁc mucosal immunity is not known.
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We have recently shown that NoV GII.4 VLPs induce
protective IgA antibodies in mucosal lavages of mice immu-
nized via intranasal (IN), but not IM, route [9]. Here, we
investigated if IM delivery of NoV GII.4 VLPs formulated
with commonly used adjuvants, Al(OH)3 or MPLA, has an
eﬀect on generation of NoV-speciﬁc mucosal immunity.
2. Materials and Methods
2.1. Recombinant NoV VLP Production. NoV GII.4-1999
(reference strain accession number AF080551) VLPs used
for immunization and as antigen in immunological assays
were produced by recombinant baculovirus technology in
Sf9 insect cells and puriﬁed as described in detail else-
where [19].
2.2. Immunization and Sample Preparation. Female 7-week-
old BALB/c OlaHsd mice (5–8 mice/experimental group)
(Envigo, Horst, the Netherlands) were immunized IM two
times (at study weeks 0 and 3) with 0.3μg dose of GII.4 VLPs
alone or formulated with 100μg of Al(OH)3 (Alhydrogel;
InvivoGen, San Diego, CA) or 5μg of MPLA from S. minne-
sota R595 (InvivoGen). In addition, two groups of mice
received a combination vaccine [20] containing 10μg GII.4
VLPs via IM and IN delivery. Mice administered IM or IN
with a carrier (sterile PBS only) served as control groups.
Immunizations were performed under general anesthesia
induced with a mixture of ketamine (Ketalar®; Pﬁzer Ltd.,
NY) and medetomidine (Dorbene®; Syva, Leon, Spain).
To test the kinetics of the antibody responses in sera, tail
blood samples (diluted 1 : 200 in PBS at the time of collec-
tion) were collected at study weeks 0 (prebleed, nonimmune
sera) and 3. Mice were sacriﬁced at study week 5 by decapita-
tion, when whole blood, intestinal secretions (feces), nasal
washes (NWs), and mesenteric lymph nodes (MLNs) were
collected. Preparation of blood samples and lymphoid tissues
was conducted according to the previously published proce-
dures [21], except a single-cell suspension from group-wise
pooled MLNs was prepared without a lysis step of red blood
cells. Fecal pellets and NWs were processed as previously
published [9, 22]. All of the experimental procedures con-
ducted were in accordance with the regulations and guide-
lines of the Finnish National Experiment Board.
2.3. Detection of NoV-Speciﬁc Serum and Mucosal Antibodies
by ELISA. Serum samples of individual mice were serially
diluted two-fold from 1 : 200 (for IgG) or 1 : 20 (for IgA)
and tested in ELISA for the presence of NoV GII.4-speciﬁc
IgG, IgG1, IgG2a, and IgA antibodies as described elsewhere
[10, 21]. Fecal suspensions (10%) and NWs were two-fold
serially diluted from 1 : 5 and studied for IgG and IgA anti-
bodies. Brieﬂy, 96-well half-area polystyrene plates (Corning
Inc., Corning, NY) were coated with 50ng of GII.4 VLPs
per well. Sample dilutions were added on the plates, and
the bound antibodies were detected with horseradish perox-
idase- (HRP-) conjugated anti-mouse IgG (Sigma-Aldrich,
St. Louis, MO), IgG1 (Invitrogen, Carlsbad, CA), IgG2a
(Invitrogen) or IgA (Sigma-Aldrich), and SIGMAFAST
OPD substrate (Sigma-Aldrich). Optical density (OD) values
at 490nm were measured by a microplate reader (Victor2
1420; PerkinElmer, Waltham, MA). A sample was consid-
ered positive if the OD490 was above the cut-oﬀ value (mean
OD490 + 3× SD of the control mice and OD490> 0.1). The
end-point titer was deﬁned as the reciprocal of the highest
dilution with an OD490 above the cut-oﬀ value. For negative
samples with the OD490 below the cut-oﬀ limit, a half of the
starting dilution was assigned for the titer.
2.4. Detection of NoV-Speciﬁc Antibody Secretion by MLN
Cells. Group-wise pooled MLN cells (4× 106 cell/ml) from
immunized mice were stimulated in vitro [23, 24] with
5μg/ml of GII.4 VLPs or culture medium (RPMI 1640 sup-
plemented with 10% FBS, 100U/ml penicillin, 100μg/ml
streptomycin, 50μM 2-mercaptoethanol, and 2mM L-
glutamine; all from Sigma-Aldrich) only. After incubation
at 37°C for 10 days, supernatants were collected and stored
at −20°C until analyzed in ELISA for anti-GII.4 IgG and
IgA antibodies as described above.
2.5. Statistical Analyses. Fisher’s exact test was employed to
assess the intergroup diﬀerences in the IgG and IgA end-
point titers. The Mann–Whitney U test and Kruskal-Wallis
test were used to compare diﬀerences between the nonpara-
metric observations of two or more independent groups.
All analyses were conducted by IBM SPSS Statistics for
Windows Version 23.0 (IBM Corp., Armonk, NY). The
statistically signiﬁcant diﬀerence was deﬁned as p ≤ 0 05.
3. Results
3.1. Induction of NoV GII.4-Speciﬁc Serum IgG and IgA
Antibodies. Eﬀect of two commonly used adjuvants on NoV
GII.4-speciﬁc serum IgG and IgA antibody responses was
investigated by immunizing the experimental mice twice
IM with 0.3 or 10μg of GII.4 VLPs alone or 0.3μg dose com-
bined with Al(OH)3 or MPLA. For comparison, one group of
mice received 10μg GII.4 VLPs via IN delivery. IM immuni-
zation with 0.3μg of GII.4 VLPs did not elicit a signiﬁcant
serum IgG response (geometric mean titer, GMT=119;
95% CI=74–192), whereas coadministration of 0.3μg VLPs
with Al(OH)3 or MPLA resulted in robust (GMTs> 5log10)
NoV GII.4-speciﬁc IgG levels (Figures 1(a) and 1(b)). Also,
IM and IN administration of 10μg dose of VLPs induced
high levels of anti-GII.4 IgG antibodies (Figures 1(a) and
1(b)). No signiﬁcant diﬀerence (p = 0 87) was observed in
the magnitude of the responses induced by 0.3μg dose of
VLPs with either of the adjuvants and 10μg dose of VLPs
via IM or IN route.
Parenteral delivery of VLPs without an adjuvant did
not elicit detectable serum anti-NoV IgA antibodies, but
very low serum IgA was observed in 1/5 mice after immu-
nizations with 0.3μg dose formulated with Al(OH)3
(GMT=13; 95% CI=6–27) or MPLA (GMT=11; 95%
CI=8–17) (Figures 1(c) and 1(d)). In contrast, IN adminis-
tration of the GII.4 VLPs alone generated a signiﬁcantly
higher (p = 0 006) IgA response (GMT=119; 95% CI= 73–
194) compared with IM administration of the adjuvanted
VLP formulations (Figures 1(c) and 1(d)). No GII.4-speciﬁc
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IgG or IgA antibodies were detected in sera of control mice
(Figures 1(a)–1(d)).
3.2. Kinetics and Th1/Th2 Dichotomy Induced by Al(OH)3
and MPLA. To study the eﬀect of Al(OH)3 and MPLA on
kinetics of serum NoV GII.4-speciﬁc antibody responses,
1 : 200 diluted sera from mice immunized IM on a two-dose
schedule at an interval of three weeks were tested for IgG
antibodies. After the ﬁrst immunization, 0.3μg dose of
GII.4 VLPs formulated with Al(OH)3 or MPLA as well as
10μg dose of VLPs alone resulted in comparable IgG
responses (p = 0 679) (Figure 2(a)). The second dose of these
antigenic formulations delivered at week 3 enhanced the
already established strong responses in all experimental
groups (p = 0 176), as observed at week 5 (Figure 2(a)).
Control mice remained negative for GII.4-speciﬁc IgG
(OD490< 0.1) during the study period (Figure 2(a)).
Determination of IgG subtype titers showed genera-
tion of both IgG1 (a marker of a Th2-type response)
(Figure 2(b)) and IgG2a (a marker of a Th1 type response)
(Figure 2(c)) antibodies by both adjuvanted GII.4 VLP for-
mulations. No statistical diﬀerence was detected in the IgG1
titers (p = 0 122) induced by 0.3μg of VLPs in the presence
of Al(OH)3 or MPLA or 10μg of VLPs alone (Figure 2(b)).
In contrast, IgG2a titers diﬀered between the experimental
groups (Figure 2(c)), Al(OH)3 adjuvanted group having
signiﬁcantly lower titers compared to other groups (p =
0 039). End-point titer IgG1/IgG2a (Th2/Th1) ratio was
2 : 1 for mice immunized with a combination of VLPs and
MPLA and 10 : 1 for VLPs and Al(OH)3. No GII.4-speciﬁc
IgG subtype antibodies were detected in sera of control mice
(Figures 2(b) and 2(c)).
3.3. Induction of NoV GII.4-Speciﬁc Antibodies in Mucosal
Secretions. In order to investigate if NoV VLPs coadminis-
tered with Al(OH)3 or MPLA induced antibodies at mucosal
surfaces, 10% fecal suspensions and NW samples of experi-
mental animals were tested for the presence of anti-GII.4
IgG and IgA antibodies. As expected, mice immunized IM
with 0.3μg dose of GII.4 VLPs alone did not develop intesti-
nal IgG antibodies (Figure 3(a)). Instead, all other experi-
mental groups had similar levels of IgG (p = 0 277) in the
intestines (Figure 3(a)).
IM delivery of VLPs in the absence of adjuvants did not
generate intestinal IgA antibodies (GMT=2.5), but fecal IgA
response was detected in 1/5 and 2/5 mice after coadminis-
tration of 0.3μg dose with Al(OH)3 (GMT=3; 95% CI=2–7)
or MPLA (GMT=5; 95% CI=2–15) (Figure 3(b)), corrobo-
rating serum IgA response (Figure 1(d)). Signiﬁcantly greater
level of IgA in the intestine (p = 0 023) was elicited by muco-
sal IN delivery of 10μg of VLPs (GMT=25; 95% CI=12–53)
(Figure 3(b)).
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Figure 1: NoV GII.4-speciﬁc systemic IgG (a, b) and IgA (c, d) antibody responses after IM immunization with 0.3 or 10μg of NoV GII.4
VLPs alone or 0.3 μg of VLPs combined with Al(OH)3 or MPLA, or IN immunization with 10 μg of VLPs alone. Group mean OD490
values with standard error of the means of IgG (a) and IgA (c) antibodies in 1 : 200 (a) and 1 : 20 (c) diluted sera of experimental
mice. Control mice received PBS only. End-point titers of IgG (b) and IgA (d) antibodies in sera of the experimental groups. Bars
represent reciprocal of log10 geometric mean titers with 95% conﬁdence intervals. The number of positive/tested mice is denoted on
each ﬁgure in parenthesis.
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Nasal lavages from experimental groups with intestinal
antibodies were also tested for the presence of GII.4-speciﬁc
IgG and IgA antibodies. Similar to fecal specimens, compara-
ble IgG levels (p = 0 902) were induced by 0.3μg of VLPs in
the presence of Al(OH)3 (GMT=6; 95% CI=2–15) or MPLA
(GMT=6; 95% CI= 4–8) via IM delivery, or by 10μg of VLPs
alone via IM (GMT=7; 95% CI=3–16) or IN delivery
(GMT=12; 95% CI=4–33) (Figure 4(a)). In contrast, only
IN administration of VLPs resulted in generation of IgA
antibodies (GMT=30; 95% CI=9–102) in the nasal secre-
tions (Figure 4(b)).
3.4. Al(OH)3 or MPLA Induced No Production of IgA
Antibodies by MLN Cells. In order to conﬁrm a lack of muco-
sal IgA antibodies induced by the two adjuvants in mucosal
secretions (Figures 3 and 4), MLN cells from Al(OH)3 and
MPLA immunized mice were tested for the production of
IgG and IgA antibodies. Cells from mice receiving VLPs in
the presence of Al(OH)3 or MPLA via IM delivery responded
with considerable IgG production to in vitro stimulation with
GII.4 VLPs (Figures 5(a) and 5(b)). On the contrary, neither
of the adjuvanted formulations induced IgA production by
MLN cells (Figures 5(a) and 5(b)), indicating that MLNs
were not inductive sites of IgA responses detected in the
intestinal secretions after IM immunization. No anti-GII.4
IgG or IgA production was detected when MLN cells were
stimulated with the culture medium only (data not shown).
4. Discussion
Protection against pathogens at mucosal surfaces is largely
dependent on secretory IgA eﬀectively induced by IN immu-
nization [25, 26]. Because of NoV transmission through
intestinal mucosa, induction of mucosal immunity to NoV
is likely a pivotal factor to be taken into consideration in
NoV vaccine development. Although parenteral immuniza-
tion routes are not generally considered potent inducers of
mucosal immunity [9, 10, 27–29], we investigated if mucosal
antibodies are induced by IM immunization of BALB/c mice
with NoV GII.4 VLPs formulated with the widely used sys-
temic adjuvants Al(OH)3, a gold standard delivery system,
or MPLA, a TLR4 agonist. It has been recently demonstrated
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Figure 2: Development of IgG (a) and IgG subtype antibodies (b, c) in mice immunized IM with 0.3 μg of GII.4 VLPs formulated with
Al(OH)3 or MPLA or 10 μg of GII.4 VLPs alone. (a) Kinetics of NoV GII.4-speciﬁc total IgG antibodies in sera of mice immunized with
the antigenic formulations at study weeks 0 and 3. Control mice received PBS only. Group mean OD490 values with standard error of the
means of individual tail blood samples collected at indicated study weeks and termination sera at week 5 are shown. End-point titrations
of anti-GII.4 IgG1 (b) and IgG2a (c) antibodies in termination sera at week 5. Mean titration curves with standard errors of the mean of
the experimental groups are shown.
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that TLR ligands (TLR3/TLR4) alter migration patterns
of dendritic cells in vivo and promote induction of mucosal
responses to codelivered antigens as a consequence of
antigen-loaded dendritic cells migrating to both draining
and nondraining lymph nodes [30]. Therefore, we also inves-
tigated if IM immunization of NoVVLP antigens codelivered
with these adjuvants causes lymphoid cell dissemination to
remote sites like MLN.
The current NoV VLP vaccine candidate in the most
advanced phases of clinical trials is administered IM in a for-
mulation with MPLA and/or Al(OH)3, being eﬀective in
inducing high systemic antibody responses [3–6]. After the
challenge, protection was seen against moderate to severe
forms of acute gastroenteritis, without signiﬁcant reductions
in NoV shedding [6]. Mucosal responses, namely, antibody-
secreting cells (ASCs) with mucosal homing phenotype,
derived from a recall of the mucosal response primed by
prior exposures to NoV may be responsible for the observed
protection [31]. In gnotobiotic calves, fecal IgA-mediated
protection from virulent bovine NoV challenge was dem-
onstrated only after mucosal (IN) immunization with
bovine NoV VLPs [32]. Several other reports have also
shown importance of mucosal immunity, especially IgA,
in protection from NoV infection [9, 11, 12]. Similarly,
parenterally delivered inactivated polio vaccine (IPV) gen-
erates protective serum antibodies but not local intestinal
mucosal antibodies in the gut, therefore being suﬃcient to
protect against disease but insuﬃcient to prevent wild
poliovirus from replicating in intestines and spreading to
the environment [33, 34].
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Figure 3: NoV GII.4-speciﬁc fecal antibody responses after IM immunization with 0.3 or 10μg of NoV GII.4 VLPs alone or 0.3 μg of VLPs
combined with Al(OH)3 or MPLA, or IN immunization with 10μg of VLPs alone. End-point titrations of anti-GII.4 IgG (a) and IgA (b)
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In this study, high levels of serum IgG antibodies were
induced by both adjuvants. Al(OH)3 and MPLA promoted
>30-fold dose sparing above nonadjuvanted dose (0.3 μg ver-
sus 10 μg dose, resp.) and induced considerable levels of
IgG1, a marker of Th2 response, as well as IgG2a, a marker
of Th1 response. Although MPLA promotes a Th1 bias [17,
35], our data showed induction of a balanced Th1/Th2-type
response by this adjuvant. In contrast, Al(OH)3 stimulated
Th2-biased response, which is in concordance with previous
observations [13, 36, 37]. A biased response depends on
several factors such as the route of delivery, animal strain,
and the vaccine antigen used, thereby explaining apparent
discrepancies of our results. Despite diﬀerent mechanisms
of the two adjuvants employed in the present study, one
being primarily a delivery or depot system and another
an immunostimulator [13], our data indicate that Al(OH)3
and MPLA work similarly for IM delivered NoV VLPs in
terms of the dose sparing, kinetics, and generation of sys-
temic IgG antibodies.
Our recent study demonstrated that IgA levels in muco-
sal tissues correlated with blocking activity, suggesting that
IgA, but not IgG, was the main antibody neutralizing NoV
on the mucosal surfaces [9]. In concordance with [9], current
results show that mucosal IgA antibodies were induced by
IN, but not IM, administration of NoV VLPs without an
adjuvant. Only low level of fecal IgA was detected in a few
mice immunized IM with NoV GII.4 VLPs and either of
the adjuvants. Because of the similarly low IgA levels in sera
of these animals, the detected antibody is likely a systemic
IgA passively exuded from serum to mucosal secretions. In
order to ensure that no NoV GII.4-speciﬁc secretory IgA
response in mucosa was missed, we also tested NWs and
vaginal washes (data not shown) for the presence of IgA
antibodies. Only IN delivery of GII.4 NoV VLPs induced
IgA antibodies in these secretions. In addition, in support
to the serum origin of IgA, no IgA ASCs were detected in
MLN cells of mice immunized with NoV VLP vaccine for-
mulated with Al(OH)3 or MPLA adjuvant. Similarly, Bessa
and colleagues have detected IgG, but not IgA, ASCs in
MLN after subcutaneous immunization of mice with a vac-
cine platform based on VLPs [38].
Our results clearly demonstrate the lack of the mucosal
IgA antibody generation in naïve animals after IM delivery
of NoV VLPs regardless of the adjuvants Al(OH)3 or MPLA
used. Others have shown that parenteral delivery (IM and
intradermal) of vaccine antigens with mucosal adjuvant
dmLT (a detoxiﬁed form of the heat-labile enterotoxin of E.
coli) promotes mucosal immunity [24], likely by inducing
mucosal homing receptors on B cells and their migration to
mucosal compartments [39], although the exact mechanism
is not completely understood. Therefore, the ﬁeld of NoV
vaccine development should consider mucosal delivery of
NoV VLP vaccines [40], or at least inclusion of mucosal
adjuvants or components targeted to mucosal traﬃcking,
to immunize naïve individuals, such as infants and young
children, to ensure induction of mucosal responses in the
gut, the port of entry for enteric viruses like NoV.
5. Conclusions
The present study demonstrates that IM administration of
NoV GII.4 VLPs formulated with Al(OH)3 or MPLA does
not induce signiﬁcant mucosal IgA antibodies in mice.
Instead, IN immunization with GII.4 VLPs alone elicited
NoV-speciﬁc mucosal immunity. These results underline
the importance of mucosal delivery route in induction of
potent mucosal responses.
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Figure 5: IgG and IgA antibodies in cells from mesenteric lymph nodes after IM immunization with 0.3 μg of NoV GII.4 VLPs formulated
with Al(OH)3 (a) or MPLA (b). End-point titration curves of anti-GII.4 IgG and IgA antibodies in cell culture supernatants from pooled
mesenteric lymph nodes (MLNs) of experimental groups stimulated in vitro with 5 μg GII.4 VLPs. Control mice received PBS only.
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